Business context and reporting period
This is Neoleukin Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, filed May 8, 2023. The request metadata names Neurogene Inc.; that does not match the registrant in the filing.
Neoleukin had discontinued development of NL-201 and, following a further restructuring in March 2023, suspended all research and development while pursuing strategic alternatives, which may include a sale, merger, asset divestiture, licensing transaction, or liquidation.
Key financial metrics
| Metric | Quarter ended March 31, 2023 | Comparable 2022 period / other detail |
|---|---|---|
| Revenue | No product revenue reported | No product revenue reported |
| Research and development expense | $7.7 million | $10.7 million |
| General and administrative expense | $4.0 million | $4.7 million |
| Property and equipment impairment | $3.4 million | None reported |
| Total operating expenses | $15.1 million | $15.4 million |
| Operating loss | $15.1 million | $15.4 million |
| Interest income | $0.9 million | $13,000 |
| Net loss | $14.2 million | $15.4 million |
| Net loss per share, basic and diluted | $0.26 | $0.28 |
| Operating cash used | $13.0 million | $14.1 million |
| Cash, cash equivalents and short-term investments | $83.4 million | $96.4 million at December 31, 2022 |
| Working capital | $78.5 million | Not stated for the comparable period |
Gross margin is not applicable to the reported business, which had no product revenue. At March 31, total assets were $98.5 million, total liabilities $17.1 million, and stockholders’ equity $81.4 million. The filing reports lease liabilities but no borrowings under debt arrangements: operating lease liabilities totaled approximately $11.4 million and finance lease liabilities approximately $0.3 million.
Material changes versus the prior comparable period
- Operating expenses were nearly flat overall, but the composition changed: R&D and G&A expenses declined, while the company recorded a $3.4 million property impairment charge related to suspending R&D.
- Net loss narrowed by about $1.1 million, primarily reflecting lower expenses and substantially higher interest income.
- Operating cash use declined by about $1.1 million. Investing activities provided $10.7 million, largely from maturities of U.S. Treasury securities; cash, cash equivalents and restricted cash decreased by $2.4 million during the quarter.
- Workforce reductions followed the November 2022 reduction of approximately 40% and the March 2023 reduction of approximately 70% of the remaining workforce. The filing says the March plan was largely completed by quarter-end; approximately 12 full-time employees remained.
Outlook, risks and unusual items
- Management believes existing cash, cash equivalents and short-term investments will fund planned operations through at least 12 months after the filing date. This estimate is based on the current plan, which excludes resuming R&D or commencing clinical trials.
- No strategic transaction is assured. The company may incur further costs during the process, and the Board may instead pursue dissolution and liquidation; any distribution to stockholders would depend on timing, obligations and reserves for contingent liabilities.
- Restructuring costs include approximately $1.7 million for the November 2022 reduction and an expected $1.8 million for the March 2023 plan. The company had accrued $2.2 million for employee severance and related costs at March 31, 2023; some remaining payments were expected through early 2024.
- The company recognized a $3.4 million impairment charge after determining that expected undiscounted cash flows from certain property and equipment were below carrying value. It also reported $4.0 million fair value of investments with unrealized losses, but no credit-loss allowance.
- Nasdaq had granted an additional compliance period through October 20, 2023 for the minimum bid-price requirement. The company said it intended to regain compliance, potentially through a reverse stock split, subject to stockholder approval.
- The filing highlights risks around failure to complete a strategic transaction, limited financing access, possible Nasdaq delisting, ongoing losses, employee retention, lease obligations, and the potential loss of value in a liquidation. The company also notes that its Form S-3 equity-raising capacity is limited by the “baby shelf” rules.
Most important facts for investors to verify
- Progress, timing, costs and terms of the strategic-alternatives process, including whether liquidation remains under consideration.
- Cash burn and runway under actual spending, particularly whether restructuring, lease and transaction costs differ from management’s assumptions.
- Nasdaq bid-price compliance status and the outcome of the proposed reverse-stock-split authorization.
- Potential stockholder dilution and voting implications, including the 12.7 million outstanding pre-funded warrants and the company’s restricted ATM capacity.
- Remaining lease commitments, severance payments and other liabilities that could reduce cash available in a transaction or liquidation.